Potential lipid-based strategies of amphotericin B designed for oral administration in clinical application
Amphotericin B (AmB) is regarded as a first-line therapy against life-threatening invasive fungal infections. Due to its poor oral bioavailability, AmB is restricted to intravenous administration in clinical practice. As science continues to move forward, two lipid-based formulations are successfull...
Bewaard in:
| Hoofdauteurs: | , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Taylor & Francis Group
2023-12-01
|
| Reeks: | Drug Delivery |
| Onderwerpen: | |
| Online toegang: | https://www.tandfonline.com/doi/10.1080/10717544.2022.2161671 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|